<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7F71BABD-BB5E-465A-A468-AD99CA3C8DA6"><gtr:id>7F71BABD-BB5E-465A-A468-AD99CA3C8DA6</gtr:id><gtr:name>Bandim Health Project (BHP)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7F71BABD-BB5E-465A-A468-AD99CA3C8DA6"><gtr:id>7F71BABD-BB5E-465A-A468-AD99CA3C8DA6</gtr:id><gtr:name>Bandim Health Project (BHP)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/2FEA791E-5E6C-4FD9-A97C-98EAEE9A1096"><gtr:id>2FEA791E-5E6C-4FD9-A97C-98EAEE9A1096</gtr:id><gtr:firstName>Hilton</gtr:firstName><gtr:surname>Whittle</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U190074200"><gtr:id>936E281F-DDFF-4509-90C4-F11910356154</gtr:id><gtr:title>A strategy to immunize young infants against measles: phase I trials</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U190074200</gtr:grantReference><gtr:abstractText>Despite the availability of a vaccine measles kills about half a million children a year. Many of these victims are young African children living in crowded towns and cities who are intensely exposed to measles before 9 months of age when the usual measles vaccines are given. Earlier vaccination is not recommended as protective proteins (antibodies) derived from the mother neutralize and inactivate the live vaccine. However, the Edmonston-Zagreb strain of measles vaccine can evoke these neutralizing antibodies. Thus we are conducting a trial of this vaccine given in two doses to Gambian infants at 4 and 9 months of age. The comparison or control group will be children given a single dose of the vaccine at 9 months of age. The protective responses generated by one or two doses of the vaccine will be measured and compared between the two groups, and the safety of early measles vaccination will be monitored.If this initial small scale trial is successful the two dose strategy will be tried in a field site in Guinea-Bissau to determine whether it protects against measles disease. If this proves true the two dose regimen will be recommended for use in Africa or other parts of the world where measles is common.</gtr:abstractText><gtr:technicalSummary>Measles kills about 1 million children a year, many of whom are infants who are too young to be vaccinated if the current strategy is followed. A two-dose regime Edmonston-Zagreb measles vaccine (E-Z) given at 6 and 9 months of age has provided protection for infants in Bissau. We propose to evaluate lowering the starting age of the two-dose regime to 4 months. Thus we will compare safety and immunogenicity of the E-Z vaccine given simultaneously with DPT at separate sites at 4 months, followed by E-Z at 9 months with a control group consisting of DPT without E-Z at 4 months followed by E-Z at nine months. Thirty children will be recruited to the treatment group and 20 to the control group.</gtr:technicalSummary><gtr:fund><gtr:end>2008-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2003-01-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>460548</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bandim Health Project (BHP)</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>nonspecific effects of measles vaccines</gtr:description><gtr:id>3B237D08-D3B1-4526-9FB2-A825E9539829</gtr:id><gtr:impact>scientific papers produced as listed</gtr:impact><gtr:outcomeId>qJd3oUtJk9K-1</gtr:outcomeId><gtr:partnerContribution>field trials in guinea Bissau</gtr:partnerContribution><gtr:piContribution>advice on design of field trials, supervision of laboratory assays for measles antibody</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>meeting with Gambia Govrnment EPI team,International meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>BF4CE3FE-72F1-45FE-9351-D03726E3E0B6</gtr:id><gtr:impact>Described the interim results of the study

a trial of two dose measlr vaccine undertaken in Guinea bissau</gtr:impact><gtr:outcomeId>080CA413727</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>OPTIMISE (11.1m euros across 18 participants)</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>8E4B1667-E5A7-469D-A172-05103CDF5911</gtr:id><gtr:outcomeId>cMppzdwYSNW0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>non-specific effects of measles vaccines</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>6C529A3C-6132-43B5-837B-D681BD25091B</gtr:id><gtr:outcomeId>jQVmnPhKWPe</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1A62077C-C8E4-487B-AE86-4894466ACD97</gtr:id><gtr:title>Immunological impact of an additional early measles vaccine in Gambian children: responses to a boost at 3 years.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2525f95c10f90a7f12efaac3a819a869"><gtr:id>2525f95c10f90a7f12efaac3a819a869</gtr:id><gtr:otherNames>Njie-Jobe J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>pm_14872_22_22314136</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F18E3E08-BD90-493C-B1B0-DDF3FCCDA2D7</gtr:id><gtr:title>Sex differences in the vaccine-specific and non-targeted effects of vaccines.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e16dca02a00616648b5fb16d77916ef0"><gtr:id>e16dca02a00616648b5fb16d77916ef0</gtr:id><gtr:otherNames>Flanagan KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>AY5HMJbVPHi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A35D3980-ECEB-4BFA-8CF8-6F405905CB48</gtr:id><gtr:title>The new decade of vaccines.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dde3ec2e4243d5f05da5c43ba88f6efc"><gtr:id>dde3ec2e4243d5f05da5c43ba88f6efc</gtr:id><gtr:otherNames>Aaby P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>pm_14872_22_22225660</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB5D36D4-80B8-41B5-AB24-A0D7E029CC99</gtr:id><gtr:title>Protective efficacy of standard Edmonston-Zagreb measles vaccination in infants aged 4.5 months: interim analysis of a randomised clinical trial.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6b192bc6c0d5ee971d43f33211f67427"><gtr:id>6b192bc6c0d5ee971d43f33211f67427</gtr:id><gtr:otherNames>Martins CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>82EE5369CF2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>27580ED6-1653-4CCD-B759-B5B7F494C571</gtr:id><gtr:title>Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dde3ec2e4243d5f05da5c43ba88f6efc"><gtr:id>dde3ec2e4243d5f05da5c43ba88f6efc</gtr:id><gtr:otherNames>Aaby P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>LRaMHjYASVt</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U190074200</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>